| Date | Title | Description |
| 06.04.2026 | Beacon Biosignals Raises $11M; Brings Series B Financing to Over $97M | Beacon Biosignals, a Boston, MA-based company leveraging brain data to advance human health, raised an $11m extension to its Series B financing, bringing the funding round to $97m the cumulative funding to over $132m.
The upsized round incl... |
| 11.01.2026 | Apella: $80 Million Raised To Bring Ambient AI And Computer Vision Into the Operating Room | Apella, a health technology company focused on operating room operations, announced it has raised $80 million in Series B financing, combining equity and venture debt, as it scales an ambient AI platform that uses computer vision to automat... |
| 09.01.2026 | Apella Raises $80M in Series B Equity and Venture Debt | Apella, a San Francisco, CA-based health technology company, raised $80M in Series B equity and venture debt
The round was led by HighlandX, with returning investors Vensana Capital, Casdin Capital, PFM Health Sciences, Upside Partnership, ... |
| 08.01.2026 | The Automated OR: Apella Secures $80M to Scale Ambient Video Intelligence Across the Surgical Suite | What You Should Know
– Apella has announced an $80M Series B round to scale its ambient AI platform designed for the most complex environment in the hospital: the operating room (OR). The round was led by HighlandX, with returning investors... |
| 18.11.2025 | Beacon Biosignals Secures $86M to Revolutionize Brain Disorder Treatment | Beacon Biosignals landed $86M in Series B funding. They plan to use it to improve diagnostics and treatment using AI. Their neurotechnology targets brain disorders. The funding helps them expand and accelerate discovery. This positions them... |
| 16.11.2025 | Beacon Biosignals: $86 Million Series B Raised To Advance AI-Driven Neurodiagnostics And Precision Neuroscience | Beacon Biosignals has raised an oversubscribed $86 million Series B to accelerate the clinical adoption of AI-powered biomarkers for neurological and psychiatric disease, expand its precision medicine data platform, and scale its neurodiagn... |
| 13.11.2025 | Beacon Biosignals Raises $86M in Series B Funding | Beacon Biosignals, a Boston, MA-based neurotechnology company powering AI-driven diagnostics and precision medicines for the brain, raised $86m in Series B funding.
Backers included Innoviva, Google Ventures (GV), Nexus NeuroTech Ventures, ... |
| 18.10.2025 | Leyden Labs Secures €30M for Groundbreaking Respiratory Nasal Spray | Leyden Laboratories, a Dutch biotechnology pioneer, recently secured a significant €30 million in equity funding. The European Innovation Council (EIC) Fund and Invest-NL spearheaded this investment. This crucial capital injection will prop... |
| 17.10.2025 | Leyden Labs: €30 Million Secured From EIC And Invest-NL | Dutch biotechnology company Leyden Laboratories B.V. has secured €30 million in new equity financing from the European Innovation Council (EIC) Fund and Invest-NL. The investment will accelerate the clinical development of the company’s pan... |
| 11.09.2025 | Octave Bioscience Secures Major Funding for Precision Neurology Advancement | Octave Bioscience secured $51.1 million in fresh capital. This includes a $35.6 million Series C equity round and a $15.5 million debt facility. Funds accelerate MSDA test commercialization. This blood-based diagnostic tool measures Multipl... |
| 10.09.2025 | Octave Bioscience: $35 Million Raised For Advancing Precision Care For Neurological Diseases | Octave Bioscience, a company focused on precision medicine for neurodegenerative conditions, has announced the successful close of a $35.6 million Series C equity financing round. In addition to this funding, the company has secured a $15.5... |
| 05.09.2025 | Octave Bioscience Raises $35M in Series C Financing | Octave Bioscience, a Menlo Park, CA-based commercial stage precision care company, announced the close of its $35.6M Series C equity financing and that it has entered into a $15.5M non-dilutive term loan agreement with Silicon Valley Bank (... |
| 14.12.2024 | The Rise of nChroma Bio: A New Dawn in Genetic Medicine | In the world of biotechnology, mergers and funding are the lifeblood of innovation. Recently, two companies, Chroma Medicine and Nvelop Therapeutics, joined forces to create nChroma Bio. This new entity is set to redefine the landscape of g... |
| 12.12.2024 | Chroma Medicine and Nvelop Therapeutics Unite to Form nChroma Bio and Raises $75M | Biotechnology companies Chroma Medicine (Boston, MA) and Nvelop Therapeutics (Cambridge, MA) announced their merger and subsequent launch of nChroma Bio to expand the R&D of the genetic medicines sector.
Concurrent with the merger, nChr... |
| 04.12.2024 | Maze Therapeutics Secures $115 Million to Revolutionize Kidney Disease Treatment | Maze Therapeutics, a beacon of innovation in the biopharmaceutical landscape, has successfully raised $115 million in a Series D financing round. This funding marks a significant milestone for the South San Francisco-based company, which is... |
| 03.12.2024 | Maze Therapeutics: $115 Million (Series D) Raised To Develop Precision Medicine | Maze Therapeutics, a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and metabolic diseases, announced the ... |
| 03.12.2024 | Maze Therapeutics Raises $115M in Series D Financing | Maze Therapeutics, a South San Francisco, CA-based clinical-stage biopharmaceutical company leveraging human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular, and metabolic disease... |
| 13.08.2024 | IDRx Raises $120 Million To Transform Cancer Treatment With Precision Therapies | IDRx (a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision therapies) announced the completion of an oversubscribed $120 million Series B Preferred Stock financing. This financin... |
| 29.07.2024 | Scorpion Therapeutics: A Bold Leap in Precision Oncology | Scorpion Therapeutics is making waves in the world of cancer treatment. With a recent $150 million Series C funding round, the Boston-based biotech is poised to redefine the landscape of precision oncology. This funding is not just a financ... |
| 27.07.2024 | TMRW Life Sciences: Pioneering the Future of Fertility Storage | In the realm of fertility treatments, the stakes are high. The management of frozen sperm, eggs, and embryos is not just a technical task; it’s a matter of life and hope. TMRW Life Sciences is stepping into this arena with a bold vision and... |
| 27.07.2024 | Scorpion Therapeutics Raises $150 Million For Enhancing Clinical-Stage Precision Oncology Pipeline | Scorpion Therapeutics, a clinical-stage oncology company dedicated to transforming the lives of cancer patients by redefining the frontier of precision oncology, announced the closing of a $150 million Series C financing. The funding was co... |
| 25.07.2024 | TMRW Life Sciences: Automated Specimen Management Company Secures Over $28 Million In Series D | TMRW Life Sciences (TMRW), the creator of the only FDA-cleared automated specimen management and storage platform for frozen human sperm, eggs, and embryos, announced that it closed a $28+ million Series D equity funding round to meet high ... |
| 24.07.2024 | TMRW Life Sciences Exceeds Series D Financing Goal To Meet Soaring Demand from Fertility Clinics Seeking Safe & More Accurate Cryostorage Solutions | Financing Led by 5AM Ventures with Participation from FIOS Venture Holdings, DF Investment Partners, Transformation Capital, Life Sciences Innovation Fund, Casdin Capital & Others
Leading Women's Health Investors & Advocates Include... |
| 02.08.2022 | Investing in IDRx | HIV ravaged entire communities before antiretroviral cocktail therapies helped turn the tide. Cocktail therapies combine multiple drugs: Some hit parts of the replication machinery the virus uses to make copies of itself, others block its a... |
| 14.01.2022 | Verana Health Raises $150M to Expand Real-World Data Network | What You Should Know:
Verana Health, a digital health company that delivers quality drug lifecycle and medical practice insights from an exclusive real-world data network, today announced a $150 million Series E funding round led by Johnson... |
| 08.11.2021 | Beacon Biosignals Secures $27M to Scale EEG Neurobiomarker Discovery Platform | What You Should Know:
– Beacon Biosignals, a neurotechnology company applying artificial intelligence to EEG (electroencephalography) to unlock precision medicine for any condition affecting the brain, has announced an oversubscribed $27M S... |
| 04.11.2021 | The SynBio Innovation Accelerator, a Collaboration between Codexis and Casdin Capital, Enables $10 million Investment in Molecular Assemblies, Inc. | Funding to accelerate MAI’s go-to-market strategy as the enzyme engineering phase nears completion
Represents the second early-stage company investment enabled by the SynBio Innovation Accelerator
REDWOOD CITY, Calif., Nov. 04, 2021 (GLOBE ... |
| 15.10.2021 | Loop Medical raises USD 6.4M to support US market entry | |
| 14.09.2021 | Vanqua Bio Launches with $85 Million Series B Financing and a Mission to Vanquish Neurodegenerative Diseases | – Novel drug-development approach combines advanced insights into critical neuronal cell pathways with cutting-edge assays to enable next-generation therapies –
– Lead program targets Parkinson’s disease and all forms of Gaucher disease –
C... |
| 15.04.2021 | C2i Genomics Raises $100M for Whole-Genome Cancer Treatment Intelligence Platform | – Cancer intelligence company, C2i Genomics announced it has raised $100M in financing from Casdin Capital, NFX, Duquesne Family Office, Section 32, iGlobe Partners, Driehaus Capital and others.
– Funds will be used to accelerate clinical d... |
| 09.04.2021 | CM LIFE SCIENCES III INC.
CM Life Sciences III Inc. : Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $552 Million Initial Public Offering | CM Life Sciences III Inc. (the “Company”) announced today that it closed its initial public offering of 55,200,000 units at $10.00 per unit, including 7,200,000 units issued pursuant to the exercise in full by the underwriters of its over-a... |
| 07.04.2021 | CM Life Sciences III Inc. :, Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $480 Million Initial Public Offering | CM Life Sciences III Inc. (the “Company”) announced today that it priced its initial public offering of 48,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“Nasdaq”) and trade under the ticker symbol ... |
| 11.03.2021 | Casdin Capital Joins $125 Million Series C for Paige | NEW YORK--(BUSINESS WIRE)--Paige, a global leader in AI-based diagnostic software in pathology, today announced that KKR, a leading global investment firm, joined Casdin Capital and Johnson & Johnson Innovation – JJDC, Inc. (JJDC) as co... |
| 22.02.2021 | CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Pricing of Upsized $240 Million Initial Public Offering | NEW YORK–(BUSINESS WIRE)–Feb 22, 2021–
CM Life Sciences II Inc. (the “ Company ”) announced today that it priced its initial public offering of 24,000,000 units at $10.00 per unit. The units will be listed on The Nasdaq Capital Market (“ Na... |
| 13.10.2020 | Casdin Capital Co-leads $57.6M Series B for Cedilla Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cedilla Therapeutics, a private biotechnology company developing targeted small molecules for the treatment of cancer and other diseases caused by protein dysregulation, today announced the closing of a $5... |
| 09.04.2020 | Casdin Capital Joins $60M Series B for Tango Therapeutics | CAMBRIDGE, Mass.--(BUSINESS WIRE)--Tango Therapeutics, a biotechnology company focused on discovering and delivering the next generation of targeted cancer therapies, today announced the closing of an oversubscribed Series B financing of $6... |
| 30.11.2017 | UPDATE: Arzeda Closes Series A on $15.2m for Plant-Based Computational Protein Production, Led by OS Fund | *First published July 27, 2017. Updated November 30 to reflect final close on $15.2 million
Seattle-based Arzeda has raised a $15.2 million Series A round to expand the capacity of its synthetic protein and enzyme development operation. The... |
| 13.01.2016 | Daily funding roundup - January 13, 2016 | Zerto secured $50M; Syros Pharmaceuticals closed $40M financing; Shape Security raised $25M funding
Bolste, provider of a business collaboration platform, announced today that it is launching its business operating system (BOS) one month af... |
| 06.01.2016 | Daily funding roundup - January 6, 2016 | Flatiron Health bagged $175M; NextCure, Inc. raised $67M; AirCloset received $8M funding
Ossia, a Bellevue, WA-based maker of a wireless power technology, received a strategic investment from Molex, LLC, a global manufacturer of electronic ... |
| 09.10.2015 | Daily funding roundup - October 14, 2015 | Area 1 Security raised $15M
eMMs, Inc. secured over $2 million in company's Series-A round of funding from private South African individual investor to build the cyber data protection fortress, FortKnoxx. Patent pending, FortKnoxx Fortress ... |
| 10.08.2015 | Genome editing company Editas gets infused with $120M | Investors in the company include Google Ventures, Khosla Ventures and Bill Gates
We like to complain about the world a lot, but this really is such a cool time to be alive. We are coming up with amazing technology at a more rapid pace than ... |
| 10.08.2015 | Daily funding roundup - August 10, 2015 | Editas Medicine Inc secured $120M; Turing Pharmaceuticals bagged $90M; Vainglory raised $26M
Editas Medicine Inc. raised $120 million from investors to support development of a technology that can precisely edit DNA and potentially treat fa... |
| - | CM Life Sciences II Inc., Sponsored by Affiliates of Casdin Capital and Corvex Management, Announces Closing of $276 Million Initial Public Offering | NEW YORK--(BUSINESS WIRE)--Feb 25, 2021--
CM Life Sciences II Inc. (the “ Company ”) announced today that it closed its initial public offering of 27,600,000 units at $10.00 per unit, including 3,600,000 units issued pursuant to the exercis... |
| - | French biotech DNA Script raises $200 million, pushes forward with desktop DNA printer | Parisian life sciences technology company DNA Script has raised $200 million in a Series C funding round. The company has developed an alternative to traditional DNA synthesis, a proprietary mechanism it calls Enzymatic DNA Synthesis. This ... |
